Syantra

Syantra has developed a novel blood-based diagnostic platform using AI and mRNA biomarker analysis to detect early systemic changes associated with cancer, focusing initially on breast cancer. Their lead product, the Syantra DX™ Breast Cancer test, aims to provide earlier and more accurate detection than traditional methods by analyzing immune system shifts rather than searching directly for tumor cells or DNA fragments. The company’s technology has received multiple innovation awards and significant research funding—including a major U.S. Department of Defense grant supporting a large multi-site clinical trial led by Cornell University and University of Calgary partners. Early results suggest high performance for early-stage breast cancer detection; full pivotal data are pending from ongoing trials.